G. Sawczyn, L. Lenfant, A. Aminsharifi, S. Kim, J. Kaouk
{"title":"Predictive factors for opioid-free management after robotic radical prostatectomy: the value of the SP® Robotic Platform.","authors":"G. Sawczyn, L. Lenfant, A. Aminsharifi, S. Kim, J. Kaouk","doi":"10.23736/S0393-2249.20.04038-2","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nThe objective was to evaluate perioperative factors associated with opioid-free management after robotic radical prostatectomy in a single institution.\n\n\nMETHODS\nFrom January 2019 to January 2020, data from patients who underwent robotic radical prostatectomy was retrospectively entered in a pre-approved IRB database. Data were analyzed according to the postoperative opioid administration in hospital and/or after discharge. Robotic radical prostatectomy was performed using either the standard multi-port Da Vinci Si robotic platform with a transperitoneal approach(MP-RALP) or the novel DaVinci SP® robotic platform with an extraperitoneal approach(SP-EPP). Patients undergoing minimally invasive surgery were included in the \"enhanced recovery after surgery\"(ERAS) protocol regardless of the surgery approach.\n\n\nRESULTS\nDuring the study period, 210 patients matched the selection criteria. Of those, 158(75%) patients received opioids during the hospital stay or after discharge and 52(25%) patients never received opioids. SP-EPP surgical approach and shorter LOS were predictors of never receiving opioids (Odds Ratio [OR]=4.97, (95% CI 1.81-14.77, p=0.002 and OR=0.56, CI 95% 0.35-0.86, p=0.011, respectively). SP-EPP surgical approach was increasing the odds of remaining opioid free whether in-hospital or after discharge (OR= 11.97, 95% CI 4.8 - 32, p<0.0001 and OR=11.6, 95% CI 4.6-31, p<0.0001, respectively). Finally, a high BMI increased the odds of receiving opioid in hospital or after discharge (OR=0.89, 95% CI 0.82-0.96, p=0.003 and OR=0.89, 95% CI 0.82-0.96, p=0.002, respectively).\n\n\nCONCLUSIONS\nIn this series, after robotic radical prostatectomy the use of a less invasive approach (SP-EPP), a shorter LOS and a lower BMI, were predictive of opioid-free status.","PeriodicalId":49015,"journal":{"name":"Minerva Urologica E Nefrologica","volume":"34 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva Urologica E Nefrologica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S0393-2249.20.04038-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 4
Abstract
BACKGROUND
The objective was to evaluate perioperative factors associated with opioid-free management after robotic radical prostatectomy in a single institution.
METHODS
From January 2019 to January 2020, data from patients who underwent robotic radical prostatectomy was retrospectively entered in a pre-approved IRB database. Data were analyzed according to the postoperative opioid administration in hospital and/or after discharge. Robotic radical prostatectomy was performed using either the standard multi-port Da Vinci Si robotic platform with a transperitoneal approach(MP-RALP) or the novel DaVinci SP® robotic platform with an extraperitoneal approach(SP-EPP). Patients undergoing minimally invasive surgery were included in the "enhanced recovery after surgery"(ERAS) protocol regardless of the surgery approach.
RESULTS
During the study period, 210 patients matched the selection criteria. Of those, 158(75%) patients received opioids during the hospital stay or after discharge and 52(25%) patients never received opioids. SP-EPP surgical approach and shorter LOS were predictors of never receiving opioids (Odds Ratio [OR]=4.97, (95% CI 1.81-14.77, p=0.002 and OR=0.56, CI 95% 0.35-0.86, p=0.011, respectively). SP-EPP surgical approach was increasing the odds of remaining opioid free whether in-hospital or after discharge (OR= 11.97, 95% CI 4.8 - 32, p<0.0001 and OR=11.6, 95% CI 4.6-31, p<0.0001, respectively). Finally, a high BMI increased the odds of receiving opioid in hospital or after discharge (OR=0.89, 95% CI 0.82-0.96, p=0.003 and OR=0.89, 95% CI 0.82-0.96, p=0.002, respectively).
CONCLUSIONS
In this series, after robotic radical prostatectomy the use of a less invasive approach (SP-EPP), a shorter LOS and a lower BMI, were predictive of opioid-free status.
研究背景:目的是评估同一机构机器人根治性前列腺切除术后无阿片类药物治疗的围手术期因素。方法:从2019年1月至2020年1月,回顾性地将接受机器人根治性前列腺切除术的患者的数据输入预批准的IRB数据库。根据术后住院和/或出院后的阿片类药物使用情况分析数据。机器人根治性前列腺切除术采用标准的多端口达芬奇Si机器人平台经腹膜入路(MP-RALP)或新型达芬奇SP机器人平台经腹膜外入路(SP- epp)进行。无论采用何种手术方式,接受微创手术的患者均被纳入“术后增强恢复”(ERAS)方案。结果在研究期间,210例患者符合选择标准。其中,158例(75%)患者在住院期间或出院后接受了阿片类药物治疗,52例(25%)患者从未接受过阿片类药物治疗。SP-EPP手术入路和较短的LOS是从未接受阿片类药物治疗的预测因素(优势比[OR]=4.97, (95% CI 1.81-14.77, p=0.002和OR=0.56, CI 95% 0.35-0.86, p=0.011)。SP-EPP手术入路增加了住院或出院后剩余阿片类药物无残留的几率(or = 11.97, 95% CI 4.8 - 32, p<0.0001; or =11.6, 95% CI 4.6-31, p<0.0001)。最后,高BMI增加了住院或出院后接受阿片类药物的几率(or =0.89, 95% CI 0.82-0.96, p=0.003和or =0.89, 95% CI 0.82-0.96, p=0.002)。结论:在本研究中,机器人根治性前列腺切除术后采用微创入路(SP-EPP),较短的LOS和较低的BMI可预测无阿片类药物状态。
期刊介绍:
The journal Minerva Urologica e Nefrologica publishes scientific papers on nephrology and urology. Manuscripts may be submitted in the form of Minerva opinion editorials, editorial comments, original articles, video illustrated articles, review articles and letters to the Editor.